# Randomized, Double-blind, Safety and Efficacy of Recombinant Human Erythropoietin in Amyotrophic Lateral Sclerosis

> **NCT03835507** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Hanyang University Seoul Hospital** · enrollment: 64 (estimated)

## Conditions studied

- Amyotrophic Lateral Sclerosis

## Interventions

- **DRUG:** recombinant human erythropoietin(rhEPO)

## Key facts

- **NCT ID:** NCT03835507
- **Lead sponsor:** Hanyang University Seoul Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-06-20
- **Primary completion:** 2020-12
- **Final completion:** 2025-12
- **Target enrollment:** 64 (ESTIMATED)
- **Last updated:** 2019-02-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03835507

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03835507, "Randomized, Double-blind, Safety and Efficacy of Recombinant Human Erythropoietin in Amyotrophic Lateral Sclerosis". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03835507. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*